Crk I inhibitors represent a specialized class of compounds targeting the Crk I protein, an adapter protein involved in various signaling pathways that regulate cellular functions such as proliferation, migration, and differentiation. Crk I is a member of the Crk family of proteins, which act as intermediaries that link activated receptors to downstream signaling cascades. By binding to specific phosphorylated tyrosine residues on other proteins, Crk I facilitates the assembly of signaling complexes that promote cellular responses to external stimuli. The modulation of Crk I activity through inhibitors can significantly influence the behavior of cells, making it an important focus for researchers studying cellular signaling mechanisms.
The development of Crk I inhibitors typically involves the identification of small molecules or peptides that can effectively disrupt the interaction between Crk I and its target proteins. These inhibitors are often designed using structure-based approaches, allowing researchers to visualize and predict how these compounds will interact with the Crk I protein. The efficacy of these inhibitors is assessed through a variety of biochemical assays that measure their ability to inhibit Crk I function and downstream signaling events. By exploring the molecular interactions and conformational changes induced by these inhibitors, scientists aim to gain deeper insights into the role of Crk I in cellular processes. As a result, Crk I inhibitors are valuable tools for dissecting complex signaling networks and understanding the functional implications of Crk I in different biological contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates into DNA and may downregulate Crk I by blocking the transcriptional elongation process necessary for Crk I mRNA production. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
As a histone deacetylase inhibitor, Trichostatin A could hyperacetylate histones near the CRK gene, leading to a tightened chromatin conformation and decreased Crk I transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor can induce hypomethylation of the CRK gene promoter, potentially leading to the silencing of Crk I gene expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
This compound binds to the guanine residues of DNA, obstructing RNA polymerase action and could thereby decrease Crk I mRNA synthesis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12 that binds to and inhibits mTOR, leading to inhibited protein synthesis machinery which could include the translation of Crk I mRNA. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 inhibits MEK1, which could lead to the downregulation of Crk I by inhibiting the ERK pathway and thus reducing the transcriptional activation of the CRK gene. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
As a PI3K inhibitor, LY 294002 could lead to decreased activation of Akt, which in turn may decrease transcriptional factors involved in CRK gene expression, reducing Crk I levels. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This JNK inhibitor could downregulate Crk I by inhibiting c-Jun N-terminal kinase, potentially decreasing the transcription of genes including CRK. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1/2, possibly leading to reduced ERK pathway signaling and consequent decrease in transcription factors that promote Crk I expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 inhibits p38 MAPK, which could lead to decreased expression of Crk I by reducing the activity of transcription factors that are activated by the p38 MAPK pathway. |